KUALA LUMPUR (July 30): Health technology company MeDKAD Sdn Bhd has announced its integration with MySejahtera, allowing those using its Covid-19 rapid antigen test to report their result to the Ministry of Health (MoH).
In a statement today, MeDKAD said its SALIXIUM rapid antigen test was launched to the market last week and is the first Malaysian-made product of its kind to have been approved by MoH for sale in Malaysia.
The product, it said, sets itself apart from other self-test kits on the market, as it requires dual swab samples of nasal and saliva specimens, which increases detection rate of viral load.
“SALIXIUM is a lateral flow assay designed for the qualitative detection of specific SARS-CoV-2 antigen in human saliva and anterior nasal swab specimen.
“It is intended to be used for the detection of SARS-CoV-2 virus infection by clinical laboratories or healthcare workers for point-of-care testing, and the public for home self-testing,” it added.
MeDKAD co-founder and CEO Ezuan Yaacob said this integration is a proactive step by MeDKAD and MoH to work together to curb the spread of the disease.
“The sensitivity of SALIXIUM is 91.23% and its specificity is recorded at 100%. The test kit passed the evaluation based on the lab results produced by the Institute of Medical Research,” he said.
Ezuan said it is the users’ responsibility to report their actual test result to avoid adverse consequences, while assisting infection prevention.
“The user must scan the unique QR code from the test device before using the test kit. After completing this process, the user must capture the image of the test device and upload through the apps and our vision artificial intelligence (AI) will validate the results.
“User’s test result, regardless whether it is positive, negative or invalid, will automatically be updated on MySejahtera and reported to the MoH,” he added.
MeDKAD said SALIXIUM is currently available for public purchase through MedCart, its health and wellness online store, and selected pharmacies.